IVIVC
A Third of Bioequivalence and Bioavailability Experts Find the Ability to Secure Biowaivers a Main Concern, Says Recent Pharma IQ Survey
June 30 by Pharma IQ NewsPharma IQ has just published the results of an industry-wide Bioequivalence and Bioavailability Survey, conducted recently among 2,000 bioequivalence and bioavailability experts. The results show...
Saving Time and Money with Transporter Studies
March 29 by Helen WinsorDominic Surry, Associate Director of In Vitro Screening & Profiling at AstraZeneca, joins Helen Winsor from Pharma IQ, to discuss clinically relevant drug transporters. He explains the importanc...
5 Top Tips on How to Establish IVIVC
April 18 by Jean-Michel CardotIVIVC is a very nice tool if you want to develop new drugs or new formulations. Why? IVIVC is very important and very nice, but mainly because you are going to study the leading factor which is going...
Guidelines are Not Recipes: Biowaivers and Beyond
April 18 by Anders FuglsangAhead of the 2nd Annual Bioequivalence and Bioavailability Studies conference, Pharma IQ caught up with Anders Fuglsang from FuglsangPharma. Fuglsang is a former EU regulator (clinical asses...